Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (401-410 of 584) with videos related to

Pageof 59
Sort By:
International Journal of Hematology|February 22, 2018
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutationsKiran Naqvi, Jorge E Cortes, Raja Luthra, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Science Advances|April 3, 2024
An in vitro neurogenetics platform for precision disease modeling in the mouseDaniel E Cortes, Mélanie Escudero, Austin C Korgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Cancer|October 21, 2016
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorshipPaul B Koller, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Blood Advances|January 4, 2018
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapyZimu Gong, L Jeffrey Medeiros, Jorge E Cortes, et al.
Pageof 59

Showing results (401-410 of 584) with videos related to

Sort By:
Pageof 59
International Journal of Hematology|February 22, 2018
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutationsKiran Naqvi, Jorge E Cortes, Raja Luthra, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Science Advances|April 3, 2024
An in vitro neurogenetics platform for precision disease modeling in the mouseDaniel E Cortes, Mélanie Escudero, Austin C Korgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Cancer|October 21, 2016
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorshipPaul B Koller, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responsesJorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Cancer|February 6, 2003
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Blood Advances|January 4, 2018
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapyZimu Gong, L Jeffrey Medeiros, Jorge E Cortes, et al.
Pageof 59